Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Ann-Katrin Schlosser

PhD Student


Phone: +49 6221 42 3822

Orcid ID: 0000-0003-1269-2537


Scientific CV

Since Sep 2022
PhD student, Immunotherapy and Immunoprevention, DKFZ, Heidelberg

2019 - 2022
MSc Molecular Biosciences with Major in Cancer Biology, Ruprecht-Karls-University and DKFZ, Heidelberg

2016 - 2019
BSc Biosciences, Ruprecht-Karls-University, Heidelberg

Research Project

Therapeutic vaccination against orthotopic HPV-dependent cancers in MHC-humanized mice

Cervical cancer, other anogenital cancers and a subset of oropharyngeal cancers are caused by persistent infection with high-risk human papillomaviruses (HPV). Current research focuses on the development of targeted immunotherapies for HPV-driven cancers, including therapeutic vaccination. Our group validated several promising HLA-restricted target epitopes derived from the HPV16 E6 and E7 oncoproteins and developed a peptide-based vaccine targeting the lead epitope HPV16 E711-19. Previous experiments already demonstrated a therapeutic potential of the vaccine in subcutaneous tumors. However, one of the major hurdles of therapeutic vaccination is to target the induced antigen-specific T cells to the correct tumor site. Therefore, we established a novel HPV16-dependent tumor model in MHC-humanized A2.DR1 mice at two biologically relevant anatomical sites, namely the female genital tract and the base of the tongue. The aim of this project is to assess the efficacy of several vaccine formulations, alone or in combination with other treatment modalities, in these two orthotopic tumor models. In the first phase of this project, tumor regression and systemic and intra-tumoral T cell responses will be assessed in tumor-bearing animals that are treated with therapeutic vaccines alone. In the second phase of this project, the vaccines will be combined with image-guided stereotactic radiotherapy and immune-checkpoint blockade.

to top
powered by webEdition CMS